This Phase 3, multicenter, double-masked, parallel-group, placebo-controlled, randomized, fixed-dose clinical study is designed to evaluate the efficacy and safety of tinlarebant (LBS-008) in subjects diagnosed with GA.

Subjects will be randomized in a 2:1 ratio to receive either tinlarebant or placebo. The study treatment will be administered orally once daily from baseline (Day 1) through the final day of Month 24.

Inclusion Criteria:

• Subjects must have a confirmed diagnosis of GA with atrophic lesions in 1 or both eyes.
• Minimum BCVA is required in the study eye

Exclusion Criteria:

• The presence of diabetic macular edema or macular disease in either eye.
• Diabetic retinopathy more advanced than mild nonproliferative diabetic retinopathy, or any other retinal vascular disease in either eye.
• Uncontrolled diagnosed glaucoma in the study eye

Eligible subjects will be randomly assigned to begin treatment in 2:1 ratio to receive the study drug (either Tinlarebant 5 mg or matching placebo)